1
|
Drevin G, Briet M, Bazzoli C, Gyan E, Schmidt A, Dombret H, Orvain C, Giltat A, Recher C, Ifrah N, Guardiola P, Hunault-Berger M, Abbara C. Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. Pharmaceutics 2022; 14:pharmaceutics14040792. [PMID: 35456626 PMCID: PMC9029035 DOI: 10.3390/pharmaceutics14040792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 03/31/2022] [Accepted: 04/01/2022] [Indexed: 02/01/2023] Open
Abstract
Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia. The aim of the study is to assess the joint daunorubicin/daunorubicinol PK profile and to define an optimal population PK study design. Fourteen patients were enrolled in the PK ancillary study of the BIG-1 trial and 6–8 samples were taken up to 24 h after administration of the first dose of daunorubicin (90 mg/m2/day). Daunorubicin and daunorubicinol quantifications were assessed using a validated liquid chromatography technique coupled with a fluorescence detector method. Data were analysed using a non-compartmental approach and non-linear mixed effects modelling. Optimal sampling strategy was proposed using the R function PFIM. The median daunorubicin and daunorubicinol AUC0-tlast were 577 ng/mL·hr (Range: 375–1167) and 2200 ng/mL·hr (range: 933–4683), respectively. The median metabolic ratio was 0.32 (range: 0.1–0.44). Daunorubicin PK was best described by a three-compartment parent, two-compartment metabolite model, with a double first-order transformation of daunorubicin to metabolite. Body surface area and plasma creatinine had a significant impact on the daunorubicin and daunorubicinol PK. A practical optimal population design has been derived from this model with five sampling times per subject (0.5, 0.75, 2, 9, 24 h) and this can be used for a future population PK study.
Collapse
Affiliation(s)
- Guillaume Drevin
- Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d’Angers, F-49100 Angers, France; (G.D.); (M.B.)
- UFR Santé, Université Angers, F-49100 Angers, France; (A.S.); (N.I.); (P.G.); (M.H.-B.)
| | - Marie Briet
- Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d’Angers, F-49100 Angers, France; (G.D.); (M.B.)
- UFR Santé, Université Angers, F-49100 Angers, France; (A.S.); (N.I.); (P.G.); (M.H.-B.)
- MITOVASC, Equipe CarMe, SFR ICAT, INSERM, CNRS, F-49000 Angers, France
| | - Caroline Bazzoli
- Grenoble INP, TIMC-IMAG, Université Grenoble Alpes, CNRS, F-38000 Grenoble, France;
| | - Emmanuel Gyan
- Service d’Hématologie et Thérapie Cellulaire, Equipe LNOx, ERL CNRS 7001, Centre Hospitalier Universitaire, Université de Tours, F-37000 Tours, France;
- Fédération Hospitalo-Universitaire GOAL, F-49033 Angers, France; (C.O.); (A.G.)
| | - Aline Schmidt
- UFR Santé, Université Angers, F-49100 Angers, France; (A.S.); (N.I.); (P.G.); (M.H.-B.)
- Fédération Hospitalo-Universitaire GOAL, F-49033 Angers, France; (C.O.); (A.G.)
- Service des Maladies du Sang, Centre Hospitalo-Universitaire d’Angers, F-49100 Angers, France
- Inserm, CRCINA, SFR ICAT, Université Angers, Université de Nantes, F-49000 Angers, France
| | - Hervé Dombret
- Blood Disease Department, University Hospital Saint Louis AP-HP, F-75010 Paris, France;
| | - Corentin Orvain
- Fédération Hospitalo-Universitaire GOAL, F-49033 Angers, France; (C.O.); (A.G.)
- Service des Maladies du Sang, Centre Hospitalo-Universitaire d’Angers, F-49100 Angers, France
| | - Aurelien Giltat
- Fédération Hospitalo-Universitaire GOAL, F-49033 Angers, France; (C.O.); (A.G.)
- Service des Maladies du Sang, Centre Hospitalo-Universitaire d’Angers, F-49100 Angers, France
| | - Christian Recher
- Insitut Universitaire du Cancer de Toulouse Oncolpole, Unversité Toulouse III Paul Sabatier, F-31000 Toulouse, France;
| | - Norbert Ifrah
- UFR Santé, Université Angers, F-49100 Angers, France; (A.S.); (N.I.); (P.G.); (M.H.-B.)
- Fédération Hospitalo-Universitaire GOAL, F-49033 Angers, France; (C.O.); (A.G.)
- Service des Maladies du Sang, Centre Hospitalo-Universitaire d’Angers, F-49100 Angers, France
| | - Philippe Guardiola
- UFR Santé, Université Angers, F-49100 Angers, France; (A.S.); (N.I.); (P.G.); (M.H.-B.)
| | - Mathilde Hunault-Berger
- UFR Santé, Université Angers, F-49100 Angers, France; (A.S.); (N.I.); (P.G.); (M.H.-B.)
- Fédération Hospitalo-Universitaire GOAL, F-49033 Angers, France; (C.O.); (A.G.)
- Service des Maladies du Sang, Centre Hospitalo-Universitaire d’Angers, F-49100 Angers, France
- Inserm, CRCINA, SFR ICAT, Université Angers, Université de Nantes, F-49000 Angers, France
| | - Chadi Abbara
- Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d’Angers, F-49100 Angers, France; (G.D.); (M.B.)
- Correspondence:
| |
Collapse
|